90944-90-4

Usage

Uses

Used in Pharmaceutical Industry:
[3-(4-CHLORO-PHENYL)-PROPYL]-METHYL-AMINE is used as a key intermediate in the synthesis of various pharmaceuticals for [application reason]. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical industry, [3-(4-CHLORO-PHENYL)-PROPYL]-METHYL-AMINE is used as a building block for the creation of novel agrochemicals, such as pesticides and herbicides, that can help improve crop yields and protect plants from harmful organisms.
Used in Research and Development:
[3-(4-CHLORO-PHENYL)-PROPYL]-METHYL-AMINE also holds potential in research and development, particularly in the field of medicinal chemistry. It can be utilized to explore new chemical reactions, develop innovative drug candidates, and enhance our understanding of molecular interactions.
Used in Organic Chemistry:
[3-(4-CHLORO-PHENYL)-PROPYL]-METHYL-AMINE is also employed in organic chemistry as a versatile building block for the synthesis of various organic compounds, contributing to the advancement of chemical research and the development of new materials with diverse applications.

Upstream product

• 2019-34-3 3-(4-chlorophenyl)propanoic acid 
• 74-89-5 methylamine 
• 1073-67-2 4-vinylbenzyl chloride 
• 51-80-9 bis-(dimethylamino)methane 

Downstream Products

• 459872-56-1 2,4-dichloro-6-{[3-(4-chlorophenyl)propyl]methylamino}-1,3,5-triazine 
• 361395-18-8 4,5,6,7-Tetrahydro-1H-benzimidazole-5-carboxylic acid [3-(4-chlorophenyl)-propyl]methylamide, hydrochloride 
• 459872-36-7 4-{4-{[3-(4-chloro-phenyl)-propyl]-methyl-amino}-6-[2-(4-hydroxy-phenyl)-ethylamino]-[1,3,5]triazin-2-yl}-piperazine-1-carboxylic acid tert-butyl ester 
• 459873-38-2 4-[2-(4-{[3-(4-chloro-phenyl)-propyl]-methyl-amino}-6-piperazin-1-yl-[1,3,5]triazin-2-ylamino)-ethyl]-phenol 
• 459872-34-5 tert-butyl 4-{4-chloro-6-[[3-(4-chlorophenyl)propyl](methyl)amino]-1,3,5-triazin-2-yl}-1-piperazinecarboxylate 

Relevant academic research and scientific papers

A General Acid-Mediated Hydroaminomethylation of Unactivated Alkenes and Alkynes

In comparison to the extensively studied metal-catalyzed hydroamination reaction, hydroaminomethylation has received significantly less attention despite its considerable potential to streamline amine synthesis. State-of-the-art protocols for hydroaminomethylation of alkenes rely largely on transition-metal catalysis, enabling this transformation only under highly designed and controlled conditions. Here we report a broadly applicable, acid-mediated approach to the hydroaminomethylation of unactivated alkenes and alkynes. This methodology employs cheap, readily available, and bench-stable reactants and affords the desired amines with excellent functional group tolerance and impeccable regioselectivity. The broad scope of this transformation, as well as mechanistic investigations and in situ domino functionalization reactions are reported.

PRODUCTION OF AMINES VIA A HYDROAMINOALKYLATION REACTION

Provided is a process for producing an amine via a hydroaminoalkylation reaction of a non-aromatic C-C double bond or C-C triple bond, said process comprising a step of reacting a compound comprising a non-aromatic C-C double bond or C-C triple bond with a reactive component which is obtainable by combining an aminal or a hemiaminal ether with an acidic medium comprising trifluoroacetic acid, wherein the aminal contains two amino groups independently selected from a secondary and a tertiary amino group that are linked by a methylene group wherein one hydrogen atom may be replaced by a further substituent, and at least one of the amino groups carries a hydrogen atom at a carbon atom bound in α-position to its nitrogen atom, and the hemiaminal ether contains a secondary or a tertiary amino group which carries a hydrogen atom at a carbon atom bound in α-position to its nitrogen atom, and the secondary or tertiary amino group is linked to an alkoxy group by a methylene group wherein one hydrogen atom may be replaced by a further substituent.

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

Chemokine receptor antagonists and methods of use therefor

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.

A new series of estrogen receptor modulators that display selectivity for estrogen receptor β

A series of 1,3,5-triazine-based estrogen receptor (ER) modulators that are modestly selective for the ERβ subtype are reported. Compound 1, which displayed modest potency and selectivity for ERβ vs ERα, was identified via high-throughput screening utiliz

Chemokine receptor anagonists and methods of use therefor

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Imidazole compounds

A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: and physiologically acceptable salts thereof.